{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T01:13:47Z","timestamp":1794100427882,"version":"4.8.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.annonc.2025.05.009","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T09:13:54Z","timestamp":1748855634000},"page":"1503-1513","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Dostarlimab and niraparib in primary advanced ovarian cancer"],"prefix":"10.1016","volume":"36","author":[{"given":"A.-C.","family":"Hardy-Bessard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Pujade-Lauraine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.G.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Montestruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Cibula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.-E.","family":"Ciuleanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Eitan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Zagouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Glasspool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Pfisterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Pha\u00ebton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.K.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bakirtzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Fauci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Kalbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.B.","family":"Musa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.R.","family":"Duska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gladieff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Braly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Thomes Pepin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.annonc.2025.05.009_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.annonc.2025.05.009_bib3","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann Oncol"},{"issue":"33","key":"10.1016\/j.annonc.2025.05.009_bib4","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1200\/JCO.22.01934","article-title":"for the PARP Inhibitors in the Management of Ovarian Cancer Guideline Expert Panel. Poly(ADP-ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update","volume":"40","author":"Tew","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2025.05.009_bib5","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-13-3141","article-title":"Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics","volume":"20","author":"Hato","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.annonc.2025.05.009_bib6","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.1158\/0008-5472.CAN-10-0153","article-title":"Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer","volume":"70","author":"Shrimali","year":"2010","journal-title":"Cancer Res"},{"issue":"14","key":"10.1016\/j.annonc.2025.05.009_bib7","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.annonc.2025.05.009_bib8","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.bbrc.2015.05.083","article-title":"The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a BRCA1(-\/-) murine model of ovarian cancer","volume":"463","author":"Huang","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"issue":"21","key":"10.1016\/j.annonc.2025.05.009_bib9","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.annonc.2025.05.009_bib10","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study","volume":"34","author":"Nanda","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2025.05.009_bib11","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.annonc.2025.05.009_bib12","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2025.05.009_bib13","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1200\/JCO.2016.34.15_suppl.5533","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent\/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: safety and clinical activity","volume":"34","author":"Disis","year":"2016","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2025.05.009_bib14","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1200\/jco.2015.33.15_suppl.5510","article-title":"Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: interim results from a phase Ib study","volume":"33","author":"Varga","year":"2015","journal-title":"J Clin Oncol"},{"issue":"suppl 6","key":"10.1016\/j.annonc.2025.05.009_bib15","doi-asserted-by":"crossref","first-page":"vi300","DOI":"10.1093\/annonc\/mdw374.18","article-title":"Safety, clinical activity and biomarkers of atezolizumab (atezo) in advanced ovarian cancer (OC)","volume":"27","author":"Infante","year":"2016","journal-title":"Ann Oncol"},{"issue":"suppl 8","key":"10.1016\/j.annonc.2025.05.009_bib16","doi-asserted-by":"crossref","first-page":"viii334","DOI":"10.1093\/annonc\/mdy285.145","article-title":"A phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa)","volume":"29","author":"Lee","year":"2018","journal-title":"Ann Oncol"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2025.05.009_bib17","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2016.34.15_suppl.3015","article-title":"Phase I study of the PD-L1 inhibitor, durvalumab (MEDI4736; D) in combination with a PARP inhibitor, olaparib (O) or a VEGFR inhibitor, cediranib (C) in women\u2019s cancers (NCT02484404)","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.annonc.2025.05.009_bib18","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.annonc.2025.05.009_bib19","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.annonc.2025.05.009_bib20","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/S0959-8049(03)00307-1","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer","volume":"39","author":"Greimel","year":"2003","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.annonc.2025.05.009_bib21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0895-4356(96)00428-3","article-title":"Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement","volume":"50","author":"Groenvold","year":"1997","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"10.1016\/j.annonc.2025.05.009_bib22","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"7","key":"10.1016\/j.annonc.2025.05.009_bib23","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/ijgc-2019-000441","article-title":"Joint ENGOT and GOG Foundation requirements for trials with industry partners","volume":"29","author":"Vergote","year":"2019","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"10.1016\/j.annonc.2025.05.009_bib24","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2025.05.009_bib25","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2025.05.009_bib26","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S1470-2045(21)00342-9","article-title":"Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial","volume":"22","author":"Monk","year":"2021","journal-title":"Lancet Oncol"},{"issue":"30","key":"10.1016\/j.annonc.2025.05.009_bib27","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1200\/JCO.23.00529","article-title":"Atezolizumab combined with bevacizumab and platinum-based therapy for platinum-sensitive ovarian cancer: placebo-controlled randomized phase III ATALANTE\/ENGOT-ov29 trial","volume":"41","author":"Kurtz","year":"2023","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.annonc.2025.05.009_bib28","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.05.009_bib29","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.ygyno.2024.07.096","volume":"190","author":"Harter","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"suppl 2","key":"10.1016\/j.annonc.2025.05.009_bib30","doi-asserted-by":"crossref","first-page":"S1223","DOI":"10.1016\/j.annonc.2024.08.2269","article-title":"LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC)","volume":"35","author":"Monk","year":"2024","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2025.05.009_bib31","article-title":"Chemotherapy with or without pembrolizumab followed by maintenance with olaparib or placebo for first-line treatment of advanced BRCA non-mutated epithelial ovarian cancer: results from the randomized phase 3 ENGOT-OV43\/GOG-3036\/KEYLYNK-001 study","volume":"35","author":"Vergote","year":"2025","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"10.1016\/j.annonc.2025.05.009_bib32","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.3390\/ijms23073871","article-title":"The Interplay between PARP inhibitors and immunotherapy in ovarian cancer: the rationale behind a new combination therapy","volume":"23","author":"Maiorano","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.annonc.2025.05.009_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1328651","article-title":"Targeting the immune microenvironment for ovarian cancer therapy","volume":"14","author":"Blanc-Durand","year":"2023","journal-title":"Front Immunol"},{"issue":"23","key":"10.1016\/j.annonc.2025.05.009_bib34","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"issue":"36","key":"10.1016\/j.annonc.2025.05.009_bib35","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1200\/JCO.24.00668","article-title":"Atezolizumab combined with platinum and maintenance niraparib for recurrent ovarian cancer with a platinum-free interval >6 months: ENGOT-OV41\/GEICO 69-O\/ANITA phase III trial","volume":"42","author":"Gonz\u00e1lez-Mart\u00edn","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2025.05.009_bib36","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.annonc.2024.05.546","article-title":"Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6\/GOG-3031\/RUBY trial","volume":"35","author":"Powell","year":"2024","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425002017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425002017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T18:06:18Z","timestamp":1768500378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753425002017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0923753425002017"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.05.009","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dostarlimab and niraparib in primary advanced ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}